These findings shed new light on the biology of ANKRD26 and could facilitate the design of novel targeted therapeutics for hereditary and acquired thrombocytopenia, such as iTTP, as well as hematological malignancies associated with abnormal ANKRD26 expression. Here, ANKRD26 is linked to hematologic disorder.